Stay updated with breaking news from Thyroid Associated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Data at Week 24 show 2.41 mm reduction in proptosis in patients treated with TEPEZZA compared with 0.92 mm in those who received placebo; 62% of TEPEZZA patients had clinically meaningful... | June 17, 2023
-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT -- -- Two patients will share their real-world experience living with TED and being... | June 5, 2023
Horizon Therapeutics plc today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease... | May 1, 2023
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease act...
-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced